Suven Life shares end with 2% gains on getting patent for drug

Shares of Suven Life Sciences ended with nearly 2 per cent gains today as the company won patent for a drug, used in treatment of neuro-degenerative diseases, in China, Eurasia and Hong Kong.
The stock went up by 1.82 per cent to settle at Rs 204.45 on BSE. During the day, it climbed 5 per cent to Rs 211.
At NSE, shares of the company jumped 1.73 per cent to close at Rs 204.85.
On the volume front, 2.04 lakh shares of the company changed hands at BSE and over 9 lakh shares were traded at NSE during the day.

The company has been granted "one product patent from China, one product patent from Eurasia and one product patent from Hong Kong corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases", it said in a BSE filing.
The patents will be valid till 2032.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally," said Venkat Jasti, CEO Suven Life.